Autoimmune diabetes vaccine (Diamyd) - Diamyd Medicalk

Drug Profile

Autoimmune diabetes vaccine (Diamyd) - Diamyd Medicalk

Alternative Names: Antigen-based therapy (ABT) - Diamyd Medical; Diabetes-mellitus-vaccine-Diamyd-Medical; Diabetes-mellitus-vaccine-Diamyd-Therapeutics; Diamyd; GAD-65 - Diamyd Medical; GAD-Alum vaccine; GAD-Alum vaccine - Diamyd Medical; GAD-antigen therapy (Diamyd); rhGAD65 - Diamyd Medical

Latest Information Update: 29 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Diamyd Medical
  • Developer Diamyd Medical AB; Linkoping University; Lund University; University of Alabama at Birmingham
  • Class Antihyperglycaemics; Diabetes mellitus vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Type 1 diabetes mellitus
  • Phase II Latent autoimmune diabetes in adults

Most Recent Events

  • 23 Oct 2018 Updated 15-month immunogenicity data from the phase I DIAGNODE-1 trial in Type-1 diabetes mellitus released by Diamyd Medical
  • 18 Sep 2018 Diamyd plans to submit a marketing application for Diamyd® in late 2020
  • 11 Sep 2018 Additional adverse events and efficacy data from the phase I DIAGNODE-1 trial in Type-1 diabetes mellitus released by Diamyd Medical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top